AMRN vs. GBIO, YMAB, HRTX, AUPH, PCRX, SYRE, RCUS, ANIP, KNSA, and AKRO
Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Generation Bio (GBIO), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical preparations" industry.
Generation Bio (NASDAQ:GBIO) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
Amarin received 804 more outperform votes than Generation Bio when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 67.86% of users gave Generation Bio an outperform vote.
Generation Bio has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Amarin has a net margin of -18.96% compared to Amarin's net margin of -1,696.87%. Generation Bio's return on equity of -9.48% beat Amarin's return on equity.
In the previous week, Generation Bio had 1 more articles in the media than Amarin. MarketBeat recorded 2 mentions for Generation Bio and 1 mentions for Amarin. Amarin's average media sentiment score of 1.40 beat Generation Bio's score of 0.00 indicating that Generation Bio is being referred to more favorably in the media.
95.2% of Generation Bio shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 21.1% of Generation Bio shares are held by company insiders. Comparatively, 2.0% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Amarin has higher revenue and earnings than Generation Bio. Amarin is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Generation Bio currently has a consensus target price of $8.00, indicating a potential upside of 140.96%. Amarin has a consensus target price of $1.08, indicating a potential upside of 53.71%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Generation Bio is more favorable than Amarin.
Summary
Generation Bio beats Amarin on 10 of the 18 factors compared between the two stocks.
Get Amarin News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
